Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK Study of OV101 in Adolescents with Fragile X or Angelman Syndrome
NCT03109756Phase 1Completed
- Sponsor
- Healx
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gaboxadol in Fragile X syndrome (FXS) and Angelman syndrome (AS), sponsored by Healx. Primary endpoints: Maximum Plasma Concentration at 10 hours, Time of Maximum Plasma Concentration at 10 hours and 4 more. Started Apr 2017; status: completed.
02
Drugs
gaboxadol
03
Conditions
Fragile X syndrome (FXS)Angelman syndrome (AS)
Beyond the preview
Go deeper on NCT03109756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109756.